Abstract
The benefit of antiplatelet therapy remains unclear, although it does appear that aspirin monotherapy started within 48 hours of stroke onset may result in a modest clinical improvement. Glicoprotein (GP) IIb/IIIa antagonists are currently considered the most powerful specific inhibitors of platelet activation in acute thrombosis. Glicoprotein IIb/IIIa inhibitor therapy could merit a prominent role also in the initial management of patients with acute ischemic stroke. Abciximab may be promising in this setting and should be evaluated in further clinical trials.
MeSH terms
-
Brain Ischemia / drug therapy
-
Fibrinolytic Agents / therapeutic use
-
Humans
-
North America
-
Platelet Activation / drug effects
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
-
Platelet Glycoprotein GPIIb-IIIa Complex / therapeutic use*
-
Randomized Controlled Trials as Topic
-
Stroke / drug therapy*
-
Tissue Plasminogen Activator / therapeutic use
-
Treatment Outcome
Substances
-
Fibrinolytic Agents
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Tissue Plasminogen Activator